Recent launches of Merck & Co.’s Lusduna (insulin glargine) in Europe, and Eli Lilly/Boehringer Ingelheim’s Basaglar (insulin glargine) in the United States, have expanded the non-innovator…
There have been significant economic benefits in Europe since the approval of the first biosimilar more than a decade ago. Although the first FDA biosimilar approval was in 2015, biosimilars are…
According to DRG epidemiology, more than 35 million people in the United States suffer migraines, and more than 10% of migraineurs suffer from chronic migraine (CM). Migraine prophylaxis is a…
Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma in the EU5 and a common indication for liver transplantation. The 2013-2015 EMA…
MARKET OUTLOOK There are multiple well-established therapies available to treat Crohn’s disease (CD). In particular, the mostly widely used biologics, the TNF-α inhibitors (e.g., Janssen/Merck…
Pulmonary hypertension (PH), particularly pulmonary arterial hypertension (PAH), is a rare but life-threatening disorder. Commercial interest in PH/PAH has increased recently due to significant…
Hyperkalemia is an important complication of chronic kidney disease (CKD) and end-stage renal disease (ESRD) with significant impacts on morbidity and mortality. Management of hyperkalemia is…
Chronic kidney disease (CKD) is a general term for a set of heterogeneous disorders that negatively affect the function and structure of the kidney. Because of the role of the kidney in many of the…
Glomerulonephritis (GN) is a condition involving inflammation of the glomerulus, which plays an important role in the filtration of blood into the kidney. If the glomerulus becomes inflamed and…
Neuropathic pain can develop after nerve lesions form at any level of the somatosensory nervous system, peripheral or central; the precise mechanisms that generate pain post-nerve injury are not…
A number of filgrastim and epoetin alfa biosimilars are available to European oncologists, and since 2015, U.S. oncologists have had access to Zarxio—the first biosimilar launched in the United…
European endocrinologists have experience in prescribing biosimilar human growth hormone and insulin glargine; however, the uptake of these biosimilars varies by each country under study. New…
Breast cancer requires a multidisciplinary treatment approach that incorporates surgery, radiotherapy, chemotherapies, and targeted therapies. Treatment decisions are influenced by disease stage,…
Using national patient-level claims data, this report analyzes physician adherence to the treatment guidelines by exploring the use of key therapies in the newly diagnosed and recently treated…
Using national patient-level claims data, this report analyzes physician adherence to the treatment guidelines by exploring the use of key therapies in the newly diagnosed and recently treated…